Restructuring Activities

6 Months Ended

Jun. 30, 2012

Restructuring and Related Activities [Abstract]

In April 2010, Caire Inc., a wholly-owned subsidiary of the Company, announced its plan to close its liquid oxygen therapy manufacturing facility in Plainfield, Indiana and relocate the manufacturing and customer service operations to a facility close to existing BioMedical operations in Canton, Georgia. The Plainfield facility was acquired as part of the 2009 acquisition of the liquid oxygen therapy business of Covidien plc. The closure was substantially completed in the second quarter of 2011. The total cost of the restructuring was approximately $7,300 which includes asset impairment charges. The cost includes cash expenditures for employee retention and separation benefits, as well as lease exit costs and loss on disposal of remaining assets.

During the three and six months ended June 30, 2012 and 2011, the Company recorded restructuring costs for employee separation benefits related to the integration of SeQual Technologies Inc., which was acquired on December 28, 2010. The Company recorded $2,280 and $2,479 for the three and six months ended June 30, 2011, respectively, related to the closure of the Plainfield, Indiana BioMedical facility. The Company also recorded $78 and $981 for the three and six months ended June 30, 2011, respectively, in restructuring costs for employee separation benefits related to the integration of SeQual Technologies Inc. These charges were recorded in cost of sales ($953 and $965 for the three and six months ended June 30, 2011, respectively) and selling, general and administrative expenses ($652 and $1,742 for the three and six months ended June 30, 2011, respectively), and loss on disposal of assets ($1,216 for the three and six months ended June 30, 2011, respectively).

The following tables summarize the Company’s restructuring activities for the three and six months ended June 30, 2012 and 2011:



	Three Months Ended June 30, 2012
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of March 31, 2012	$	—	$	42		$	507		$	—	$	549
Restructuring charges	—		—			5			—		5
Cash payments and other	—		(36		)	(287		)	—		(323		)
Balance as of June 30, 2012	$	—	$	6		$	225		$	—	$	231



	Six Months Ended June 30, 2012
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of January 1, 2012	$	—	$	115		$	998		$	—	$	1,113
Restructuring charges	—		—			31			—		31
Cash payments and other	—		(109		)	(804		)	—		(913		)
Balance as of June 30, 2012	$	—	$	6		$	225		$	—	$	231



	Three Months Ended June 30, 2011
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of March 31, 2011	$	64		$	258		$	2,400		$	—		$	2,722
Restructuring charges	—			27			2,358			437			2,822
Loss on disposal of assets	—			—			(1,216		)	—			(1,216		)
Cash payments and other	(64		)	(129		)	(1,576		)	(437		)	(2,206		)
Balance as of June 30, 2011	$	—		$	156		$	1,966		$	—		$	2,122



	Six Months Ended June 30, 2011
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of January 1, 2011	$	103		$	387		$	2,088		$	—		$	2,578
Restructuring charges	—			26			3,460			437			3,923
Loss on disposal of assets	—			—			(1,216		)	—			(1,216		)
Cash payments and other	(103		)	(257		)	(2,366		)	(437		)	(3,163		)
Balance as of June 30, 2011	$	—		$	156		$	1,966		$	—		$	2,122

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References+ Details